GlassScriptPhysician profile
Virgilio C Ereso
NPI 1720031685
$5,630.30
in general payments reported to CMS, 2019-2025
30 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $456 · 2021: $730 · 2022: $933 · 2023: $1,101 · 2024: $1,109 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,132 · Education: $32.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,131.65 |
| Education | $32.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,497.90 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $885.54 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $784.78 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Lilly USA, LLC | $319.78 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $208.71 | 2019-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $205.89 | 2023-2025 | |
| Glaxosmithkline, LLC. | $192.51 | 2021-2025 | Trelegy Ellipta |
| Pfizer INC. | $188.91 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.94 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $145.19 | 2023-2025 | |
| Amarin Pharma, INC. | $138.93 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $116.16 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $100.73 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $82.34 | 2021-2022 | |
| Allergan, INC. | $72.80 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $69.11 | 2019-2024 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $64.33 | 2022 | |
| Ironwood Pharmaceuticals, INC | $57.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.71 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $50.37 | 2021-2022 | |
| Mylan Specialty L.P. | $37.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $33.33 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Philips North America LLC | $32.34 | 2019 | |
| Radius Health, INC. | $27.40 | 2025 | |
| Alexion Pharmaceuticals, INC. | $17.71 | 2021 | |
| Abbvie INC. | $16.66 | 2022 | |
| Averitas Pharma INC. | $14.65 | 2023 | Qutenza |
| Seqirus USA INC | $13.22 | 2022 | |
| Opko Pharmaceuticals, LLC | $13.04 | 2023 | Rayaldee |
| Biohaven Pharmaceuticals, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virgilio Ereso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.